Medical Therapy. Adverse Effects or Lack of Adverse Effects

Treprostinil in Neonates with Congenital Diaphragmatic Hernia-Related Pulmonary Hypertension

Felix R. De Bie, Catherine M. Avitabile, Sabrina Flohr, Sierra Land, Leny Mathew, Yan Wang, Devon Ash, Natalie E. Rintoul, Holly L. HedrickChildren’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine. Cluster Woman and Child. United States and Belgium Journal of PediatricsJ Pediatr 2023; DOI: 10.1016/j.jpeds.2023.113420 AbstractObjective: To describe our experience with treprostinil, evaluate […]

Treprostinil in Neonates with Congenital Diaphragmatic Hernia-Related Pulmonary Hypertension Read More »

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis

Fen Cao, Kun Wu, Yongzhi Zhu, Junjun Jiang, Gui Zhang, Jun Liu, Ping Xiao, Yang Tian, Wei Zhang, Sheng Zhang, Feng Hou, Zhongwu BaoHuaihua First People’s Hospital.China Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2023; 9: DOI: 10.3389/fcvm.2022.1055897 AbstractBackground: Pulmonary arterial hypertension (PAH) is a fatal disease characterized by pulmonary vascular remodeling and increased pulmonary artery pressure, leading

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis Read More »

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. VargheseTexas Children’s Hospital and Baylor College of Medicine.United States Frontiers in PediatricsFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1050508 AbstractSelexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration Read More »

Propranolol Therapy for Congenital Chylothorax

Roxane Handel-Orefice, Bevin Midura, June K. Wu, Elvira Parravicini, Russell S. Miller, Carrie J. ShawberColumbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Morgan Stanley Children’s HospitalUnited States PediatricsPediatrics 2023; 151: DOI: 10.1542/peds.2022-058555 AbstractCongenital chylothorax is a rare and often severe anomaly without well-established medical therapies. Previously, propranolol use in patients with lymphatic malformations

Propranolol Therapy for Congenital Chylothorax Read More »

Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension

Yan Wu, Fu-Hua Peng, Xin Gao, Xin-Xin Yan, FengWen Zhang, Jiang-Shan Tan, Song Hu, Lu HuaFuwai Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College.China Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; DOI: 10.3389/fcvm.2022.918735 AbstractBackground: Chronic calcium channel blockers (CCBs) are indicated in children with idiopathic/heritable pulmonary arterial hypertension (IPAH/HPAH) and positive response to

Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension Read More »

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease

Yuka Hanaki, Jun Muneuchi, Junko Yamamoto, Chie Yokota, Junya Ohmura, Hiroki Ezaki, Miwa Yoshino, Ryoko Nakamura, Miho Takeichi, Yuichiro Sugitani, Ryouhei Matsuoka, Hirohito Doi, Mamie Watanabe, Yasukiko TakahashiKyushu Hospital and Japan Community Healthcare Organization. Japan Pediatric CardiologyPediatr Cardiol 2022; 43: 1131-1135DOI: 10.1007/s00246-022-02834-y AbstractHigh-flow nasal cannula (HFNC) therapy has been applied in the perioperative respiratory care for

Home High-Flow Nasal Cannula Therapy in Children with Congenital Heart Disease Read More »

Bleeding Complications in Neonates Receiving Extracorporeal Membrane Oxygenation and Controlled Hypothermia

Swosti Joshi, Vilmaris Quinones Cardona, Erica Poletto, Ogechukwu MenkitiDrexel University College of Medicine Philadelphia. Saint Christopher’s Hospital for Children.United States American Journal of PerinatologyAm J Perinatol 2022; DOI: 10.1055/a-1786-8688 AbstractObjective: Safety and efficacy data on controlled hypothermia (CH) for neonates with moderate to severe hypoxic ischemic encephalopathy has been extrapolated to a subgroup of these patients who

Bleeding Complications in Neonates Receiving Extracorporeal Membrane Oxygenation and Controlled Hypothermia Read More »

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis

Jun Yasuhara, Kae Watanabe, Atsuyuki Watanabe, Takuro Shirasu, Yuichi Matsuzaki, Hirofumi Watanabe, Hisato Takagi, Naokata Sumitomo, Toshiki KunoNationwide Children’s Hospital. Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine. University of Tsukuba Hospital. University of Virginia. McGill University. Medical University of South Carolina. Shizuoka Medical Center. Saitama Medical

Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis Read More »

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use

Walid A. Hussain, Deborah S. Bondi, Pooja Shah, Sherwin E. Morgan, Sudhir Sriram, Michael D. SchreiberLoyola University Medical Center. University of Chicago Medicine Comer Children’s Hospital. United States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2022; 27: 284-291DOI: 10.5863/1551-6776-27.3.284 AbstractObjective: Inhaled nitric oxide (iNO) is an effective but expensive treatment of pulmonary hypertension in newborns,

Implementation of an Inhaled Nitric Oxide Weaning Protocol and Stewardship in a Level 4 NICU to Decrease Inappropriate Use Read More »

Oral hymecromone decreases hyaluronan in human study participants

Joelle I. Rosser, Nadine Nagy, Riya Goel, Gernot Kaber, Sally Demirdjian, Jamie Saxena, Jennifer B. Bollyky, Adam R. Frymoyer, Ana E. Pacheco-Navarro, Elizabeth B. Burgener, Jayakumar Rajadas, Zhe Wang, Olga Arbach, Colleen E. Dunn, Anissa Kalinowski, Carlos E. Milla, Paul L. BollykyStanford University. UCSF School of Pharmacy. Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin

Oral hymecromone decreases hyaluronan in human study participants Read More »

Scroll to Top